All Stories

  1. Prevalence of children’s mental health disorders and implications in pharmacotherapy: a systematic review and meta-analysis

    Article • Postgraduate Medicine, July 2025, Taylor & Francis

    Dr. Qing Ma

  2. Pharmacists' contributions to the management of opioid use disorder

    Article • JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, June 2025, Wiley

    Dr. Qing Ma

  3. Comparison of Pyrazinamide with Isoniazid for Their Effects on the Heme Biosynthetic Pathway in Mouse Liver

    Article • Metabolites, May 2025, MDPI AG

    Dr. Qing Ma

  4. The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With Human Immunodeficiency Virus (HIV)

    Article • Clinical Infectious Diseases, December 2024, Oxford University Press (OUP)

    Dr. Qing Ma

  5. Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV

    Article • The Journal of Infectious Diseases, December 2023, Oxford University Press (OUP)

    Dr. Qing Ma

  6. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights

    Article • Drug Design Development and Therapy, July 2022, Taylor & Francis

    Dr. Qing Ma

  7. The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV

    Article • Journal of NeuroVirology, April 2022, Springer Science + Business Media

    Dr. Qing Ma

  8. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial

    Article • Clinical Infectious Diseases, February 2022, Oxford University Press (OUP)

    Dr. Qing Ma

  9. Polypharmacy in older adults with HIV infection: Effects on the brain

    Article • Journal of the American Geriatrics Society, December 2021, Wiley

    Dr. Qing Ma

  10. Soluble Biomarkers of Cognition and Depression in Adults with HIV Infection in the Combination Therapy Era

    Article • Current HIV/AIDS Reports, November 2021, Springer Science + Business Media

    Dr. Qing Ma

  11. Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China

    Article • Journal of Infection and Public Health, September 2021, Elsevier

    Dr. Qing Ma

  12. Pharmacokinetic drug interactions of integrase strand transfer inhibitors

    Article • Current Research in Pharmacology and Drug Discovery, January 2021, Elsevier

    Dr. Qing Ma

  13. Mentored postdoctoral training in Zimbabwe: A report on a successful collaborative effort

    Article • Journal of Public Health in Africa, March 2020, PAGEPress Publications

    Dr. Qing Ma, Dr. Danai Tavonga Zhou

  14. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB)

    Article • Journal of Neuroimmune Pharmacology, January 2020, Springer Science + Business Media

    Dr. Qing Ma

  15. Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants

    Article • January 2020, Springer Science + Business Media

    Dr. Qing Ma

  16. CNS Neurotoxicity of Antiretrovirals

    Article • Journal of Neuroimmune Pharmacology, December 2019, Springer Science + Business Media

    Dr. Qing Ma

  17. Benzodiazepine Use Is Associated With an Increased Risk of Neurocognitive Impairment in People Living With HIV

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2019, Wolters Kluwer Health

    Dr. Qing Ma

  18. A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, November 2019, Wiley

    Dr. Qing Ma

  19. Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

    Article • Clinical Infectious Diseases, September 2019, Oxford University Press (OUP)

    Dr. Qing Ma

  20. Plasma brain-derived neurotrophic factor (BDNF) concentration and the BDNF Val66Met polymorphism in suicide: a prospective study in patients with depressive disorder

    Article • Pharmacogenomics and Personalized Medicine, July 2019, Dove Medical Press

    Dr. Qing Ma, ming Ai

  21. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study

    Article • The Lancet HIV, July 2019, Elsevier

    Dr. Qing Ma

  22. Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients

    Article • Expert Review of Clinical Pharmacology, May 2019, Taylor & Francis

    Dr. Qing Ma

  23. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

    Article • Antimicrobial Agents and Chemotherapy, January 2019, ASM Journals

    Dr. Qing Ma

  24. Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid

    Article • Journal of Pharmaceutical and Biomedical Analysis, July 2018, Elsevier

    Dr. Qing Ma

  25. Development and validation of a UHPLC-MS/MS assay for elvitegravir measurement in human plasma and cerebrospinal fluid

    Article • Separation Science Plus, April 2018, Wiley

    Dr. Qing Ma

  26. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants

    Article • Therapeutic Drug Monitoring, December 2017, Wolters Kluwer Health

    Dr. Qing Ma

  27. Translational pharmacology and HIV reservoir eradication strategies

    Article • Future Virology, October 2017, Future Medicine

    Dr. Qing Ma

  28. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, September 2017, Wiley

    Dr. Qing Ma

  29. Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population

    Article • Expert Review of Clinical Pharmacology, August 2017, Taylor & Francis

    Dr. Qing Ma

  30. Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals

    Article • Journal of NeuroVirology, August 2017, Springer Science + Business Media

    Dr. Qing Ma

  31. Aspirin responsiveness changes in obese patients following bariatric surgery

    Article • Cardiovascular Therapeutics, July 2017, Wiley

    Dr. Qing Ma

  32. Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

    Article • The Journal of Infectious Diseases, July 2017, Oxford University Press (OUP)

    Dr. Qing Ma

  33. Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy

    Article • AIDS, March 2017, Wolters Kluwer Health

    Dr. Qing Ma

  34. Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

    Article • Clinical Pharmacology in Drug Development, March 2017, Wiley

    Dr. Qing Ma

  35. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders

    Article • Current Vascular Pharmacology, March 2016, Bentham Science Publishers

    Dr. Qing Ma

  36. Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

    Article • AIDS Research and Treatment, January 2016, Hindawi Publishing Corporation

    Dr. Qing Ma

  37. Pharmacogenomics and Antiretroviral Therapy: Pharmacogenomics of HIV-1 Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors - Implications for Personalized Antiretroviral Therapy

    Article • December 2015, Bentham Science Publishers

    Dr. Qing Ma

  38. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

    Article • Journal of NeuroVirology, September 2015, Springer Science + Business Media

    Dr. Qing Ma

  39. Recent advances in management of the HIV/HCV coinfected patient

    Article • Future Virology, August 2015, Future Medicine

    Dr. Qing Ma

  40. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

    Article • PLOS One, June 2015, PLOS

    Dr. Qing Ma

  41. Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2014, Wolters Kluwer Health

    Dr. Qing Ma

  42. Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures

    Article • Journal of Orthopaedic Surgery and Research, November 2014, Springer Science + Business Media

    Dr. Qing Ma

  43. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

    Article • Journal of Antimicrobial Chemotherapy, August 2014, Oxford University Press (OUP)

    Dr. Qing Ma

  44. Corrections

    Article • The Lancet Infectious Diseases, June 2014, Elsevier

    Dr. Qing Ma

  45. Determination of Amikacin in Different Pharmaceutical Formulations Using a Resonance Rayleigh Scattering Method with Pontamine Sky Blue

    Article • Current Pharmaceutical Analysis, April 2014, Bentham Science Publishers

    Dr. Qing Ma

  46. Single-tablet, once-daily treatment regimens for HIV

    Article • The Lancet Infectious Diseases, April 2014, Elsevier

    Dr. Qing Ma

  47. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy

    Article • Journal of Antimicrobial Chemotherapy, January 2014, Oxford University Press (OUP)

    Dr. Qing Ma

  48. Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine

    Article • Clinical Infectious Diseases, November 2013, Oxford University Press (OUP)

    Dr. Qing Ma

  49. Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism

    Article • American Journal on Addictions, October 2013, Wiley

    Dr. Qing Ma

  50. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients

    Article • Journal of NeuroVirology, June 2013, Springer Science + Business Media

    Dr. Qing Ma

  51. Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients

    Article • AIDS Research and Treatment, January 2013, Hindawi Publishing Corporation

    Dr. Qing Ma

  52. Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry

    Article • Journal of Chromatography B, May 2012, Elsevier

    Dr. Qing Ma

  53. Global HIV/AIDS Clinical and Translational Pharmacology

    Article • AIDS Research and Treatment, January 2012, Hindawi Publishing Corporation

    Dr. Qing Ma

  54. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults

    Article • AIDS Research and Treatment, January 2012, Hindawi Publishing Corporation

    Dr. Qing Ma

  55. The Impact of Herbal Drug Use on Adverse Drug Reaction Profiles of Patients on Antiretroviral Therapy in Zimbabwe

    Article • AIDS Research and Treatment, January 2012, Hindawi Publishing Corporation

    Dr. Qing Ma

  56. Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir

    Article • Clinical Infectious Diseases, November 2011, Oxford University Press (OUP)

    Dr. Qing Ma

  57. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans

    Article • HIV Medicine, November 2011, Wiley

    Dr. Qing Ma

  58. Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV Infection

    Article • PLOS One, October 2011, PLOS

    Dr. Qing Ma

  59. Pharmacologic approaches to the treatment of Huntington's disease

    Article • Movement Disorders, October 2011, Wiley

    Dr. Qing Ma

  60. Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders

    Article • Therapeutic Drug Monitoring, June 2011, Wolters Kluwer Health

    Dr. Qing Ma

  61. Drug Interactions in the Treatment and Chemoprophylaxis of Malaria in HIV Infected Individuals in Sub Saharan Africa

    Article • Current Drug Metabolism, January 2011, Bentham Science Publishers

    Dr. Qing Ma

  62. Within-Patient Atazanavir Trough Concentration Monitoring in HIV-1-Infected Patients

    Article • Journal of Pharmacy Practice, November 2010, SAGE Publications

    Dr. Qing Ma

  63. CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients

    Article • Therapeutic Drug Monitoring, October 2010, Wolters Kluwer Health

    Dr. Qing Ma

  64. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, August 2010, Wolters Kluwer Health

    Dr. Qing Ma

  65. Therapeutic drug monitoring in highly active antiretroviral therapy

    Article • Expert Opinion on Drug Safety, March 2010, Informa Healthcare

    Dr. Qing Ma

  66. Host Proteome Research in HIV Infection

    Article • Genomics Proteomics & Bioinformatics, March 2010, Elsevier

    Dr. Qing Ma

  67. Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir

    Article • American Journal on Addictions, January 2010, Wiley

    Dr. Qing Ma

  68. Lack of Clinically Significant Drug Interactions between Nevirapine and Buprenorphine

    Article • American Journal on Addictions, January 2010, Wiley

    Dr. Qing Ma

  69. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia

    Article • Haemophilia, December 2009, Wiley

    Dr. Qing Ma

  70. Pharmacogenomics ofCYP3A: considerations for HIV treatment

    Article • Pharmacogenomics, August 2009, Future Medicine

    Dr. Qing Ma

  71. Research in Women and Special Populations

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, September 2008, Wiley

    Dr. Qing Ma

  72. Pharmacogenomics and HIV pharmacotherapy

    Article • Expert Review of Clinical Pharmacology, January 2008, Taylor & Francis

    Dr. Qing Ma

  73. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers

    Article • Biopharmaceutics & Drug Disposition, January 2008, Wiley

    Dr. Qing Ma

  74. Antiretroviral Therapy

    Article • Clinical Pharmacokinetics, January 2008, Springer Science + Business Media

    Dr. Qing Ma

  75. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir

    Article • Drug and Alcohol Dependence, December 2007, Elsevier

    Dr. Qing Ma

  76. Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring

    Article • Therapeutic Drug Monitoring, October 2007, Wolters Kluwer Health

    Dr. Qing Ma

  77. Advances in pharmacogenomics of antiretrovirals: an update

    Article • Pharmacogenomics, September 2007, Future Medicine

    Dr. Qing Ma

  78. Development of oral anticoagulants

    Article • British Journal of Clinical Pharmacology, September 2007, Wiley

    Dr. Qing Ma

  79. Review of HIV-1 Protease Inhibitor Assay Methods

    Article • Current Pharmaceutical Analysis, August 2007, Bentham Science Publishers

    Dr. Qing Ma

  80. Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

    Article • Current Pharmaceutical Design, May 2007, Bentham Science Publishers

    Dr. Qing Ma

  81. Drug interactions between proton pump inhibitors and antiretroviral drugs

    Article • Expert Opinion on Drug Metabolism & Toxicology, April 2007, Informa Healthcare

    Dr. Qing Ma

  82. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV

    Article • Pharmacogenomics, March 2007, Future Medicine

    Dr. Qing Ma

  83. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides

    Article • Thrombosis Research, January 2007, Elsevier

    Dr. Qing Ma

  84. Factors Associated with Altered Pharmacokinetics in Substance Users and Non-Substance Users Receiving Lopinavir and Atazanavir

    Article • American Journal on Addictions, January 2007, Wiley

    Dr. Qing Ma

  85. Critical Pathways: The Role of Pharmacy Today and Tomorrow

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, September 2006, Wiley

    Dr. Qing Ma

  86. Update on the Pharmacokinetic Aspects of Antiretroviral Agents: Implications in Therapeutic Drug Monitoring

    Article • Current Pharmaceutical Design, March 2006, Bentham Science Publishers

    Dr. Qing Ma

  87. Pharmacokinetics and Pharmacodynamics of Enoxaparin in Multiple Trauma Patients

    Article • Journal of Trauma and Acute Care Surgery, December 2005, Wolters Kluwer Health

    Dr. Qing Ma

  88. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

    Article • Expert Opinion on Drug Metabolism & Toxicology, September 2005, Informa Healthcare

    Dr. Qing Ma

  89. Therapeutic Drug Monitoring: Role for a Pharmacist in Multidisciplinary Antiretroviral Management

    Article • Journal of Pharmacy Practice, August 2005, SAGE Publications

    Dr. Qing Ma

  90. Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2005, SAGE Publications

    Dr. Qing Ma

  91. Studies on the Effect of Calcium in Interactions Between Heparin and Heparin Cofactor II Using Surface Plasmon Resonance

    Article • Clinical and Applied Thrombosis/Hemostasis, July 2004, SAGE Publications

    Dr. Qing Ma

  92. Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile

    Article • Current Pharmaceutical Design, April 2004, Bentham Science Publishers

    Dr. Qing Ma

  93. Differentiation of Low-Molecular-Weight Heparins: Impact on the Future of the Management of Thrombosis

    Article • Seminars in Thrombosis and Hemostasis, February 2004, Thieme Publishing Group

    Dr. Qing Ma

  94. Molecular and Pharmacologic Profile of Tinzaparin and A Comparable Low-Molecular-Weight Bacterial Sulfaminoheparosan

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2004, SAGE Publications

    Dr. Qing Ma

  95. Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology

    Article • Seminars in Cardiothoracic and Vascular Anesthesia, December 2003, SAGE Publications

    Dr. Qing Ma

  96. Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation

    Article • Clinical and Applied Thrombosis/Hemostasis, October 2003, SAGE Publications

    Dr. Qing Ma

  97. Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates

    Article • Thrombosis Research, January 2003, Elsevier

    Dr. Qing Ma

  98. Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2003, SAGE Publications

    Dr. Qing Ma

  99. Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin

    Article • Clinical Pharmacokinetics, January 2003, Springer Science + Business Media

    Dr. Qing Ma

  100. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies

    Article • Thrombosis Research, April 2002, Elsevier

    Dr. Qing Ma

  101. Reference Intervals of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited

    Article • Clinical and Applied Thrombosis/Hemostasis, April 2002, SAGE Publications

    Dr. Qing Ma

  102. The blood–brain barrier accessibility of a heparin-derived oligosaccharides C3

    Article • Thrombosis Research, March 2002, Elsevier

    Dr. Qing Ma

  103. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3

    Article • Thrombosis Research, February 2002, Elsevier

    Dr. Qing Ma

  104. Reference Ranges of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2002, SAGE Publications

    Dr. Qing Ma

  105. Inhibition of Tissue Factor-Activated Platelets by Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Receptor Antagonist

    Article • Thrombosis Research, April 2001, Elsevier

    Dr. Qing Ma

  106. Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture

    Article • Clinical and Applied Thrombosis/Hemostasis, April 2001, SAGE Publications

    Dr. Qing Ma

  107. Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats

    Article • Brain Research, February 2000, Elsevier

    Dr. Qing Ma